Page last updated: 2024-12-11
elisidepsin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
elisidepsin: antineoplastic; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
elisidepsin : A synthetic cyclodepsipeptide derived from a marine metabolite that exhibits antineoplastic properties. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 9855343 |
| CHEBI ID | 83152 |
| SCHEMBL ID | 12942464 |
| MeSH ID | M0512928 |
Synonyms (19)
| Synonym |
|---|
| elisidepsin |
| elisidepsin [inn] |
| 0fwr494ec9 , |
| unii-0fwr494ec9 |
| 13,8-anhydro(n-((4s)-4-methylhexanoyl)-d-valyl-l-threonyl-l-valyl-d-valyl-d-prolyl-l-ornithyl-d-alloisoleucyl-d-allothreonyl-d-alloisoleucyl-d-valyl-l-phenylalanyl-(2z)-2-aminobut-2-enoyl-l-valine) |
| 681272-30-0 |
| CHEBI:83152 |
| n-[(4s)-4-methylhexanoyl]-d-valyl-l-threonyl-l-valyl-d-valyl-d-prolyl-l-ornithyl-n-{(3s,6z,9s,12r,15r,18r,19r)-9-benzyl-15-[(2s)-butan-2-yl]-6-ethylidene-3,12-diisopropyl-19-methyl-2,5,8,11,14,17-hexaoxo-1-oxa-4,7,10,13,16-pentaazacyclononadecan-18-yl}-d- |
| SCHEMBL12942464 |
| n-((4s)-4-methyl-1-oxohexyl)-d-valyl-l-threonyl-l-valyl-d-valyl-d-prolyl-l-ornithyl-d-alloisoleucyl-d-allothreonyl-d-alloisoleucyl-d-valyl-l-phenylalanyl-(2z)-2-amino-2-butenonyl-l-valine (13->8)-lactone |
| elisidepsin [mi] |
| 1-(n-((4s)-4-methyl-1-oxohexyl)-d-valine)kahalalide f |
| isokahalalide f |
| l-valine, n-((4s)-4-methyl-1-oxohexyl)-d-valyl-l-threonyl-l-valyl-d-valyl-d-prolyl-l-ornithyl-d-alloisoleucyl-d-allothreonyl-d-alloisoleucyl-d-valyl-l-phenylalanyl-(2z)-2-amino-2-butenoyl-, (13-8)-lactone |
| elisidepsin [who-dd] |
| Q27156668 |
| DTXSID501026290 |
| CS-0007487 |
| HY-13621 |
Research Excerpts
Overview
Elisidepsin is a drug with antiproliferative activity in a wide range of tumors. It is a marine-derived anti-tumor agent.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Elisidepsin is a marine-derived anti-tumor agent with unique mechanism of action. " | ( ErbB protein modifications are secondary to severe cell membrane alterations induced by elisidepsin treatment. Galmarini, CM; Lisboa, D; Molina-Guijarro, JM; Nagy, P; Roszik, J; Szöllosi, J; Váradi, T; Vereb, G, 2011) | 2.03 |
| "Elisidepsin is a drug with antiproliferative activity in a wide range of tumors." | ( Epithelial-mesenchymal transition markers and HER3 expression are predictors of elisidepsin treatment response in breast and pancreatic cancer cell lines. Aracil, M; Hernández-Losa, J; Marés, R; Ramón y Cajal, S; Teixidó, C, 2013) | 1.34 |
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| " The pharmacokinetic profile of drug-loaded solid lipid nanoparticles was also evaluated in Beagle dogs and compared with that of a cyclodextrin-based delivery system by means of AUC, C(max) and T(max) parameter estimation." | ( Comparison of pharmacokinetic profiles of PM02734 loaded lipid nanoparticles and cyclodextrins: in vitro and in vivo characterization. Avilés, P; Bishop, A; Blanco-Prieto, MJ; Calvo, P; Estella-Hermoso de Mendoza, A, 2012) | 0.38 |
Compound-Compound Interactions
Infra-optimal doses of elisidepsin and carboplatin and a lack of antitumor activity do not warrant further clinical development for these two combinations.
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients were randomized to one of two elisidepsin dosing schedules." | ( Phase Ib/II study of elisidepsin in metastatic or advanced gastroesophageal cancer (IMAGE trial). Alsina, M; Anthoney, A; Bohan, P; Brown, J; Gonçalves, A; Gunzer, K; Iglesias Dios, JL; Laus, G; Metges, JP; Miguel-Lillo, B; Montagut, C; Petty, R; Salazar, R, 2016) | 1.02 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Roles (1)
| Role | Description |
|---|---|
| antineoplastic agent | A substance that inhibits or prevents the proliferation of neoplasms. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Drug Classes (1)
| Class | Description |
|---|---|
| cyclodepsipeptide | A depsipeptide in which the amino and hydroxy carboxylic acid residues are connected in a ring. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Research
Studies (21)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (19.05) | 29.6817 |
| 2010's | 17 (80.95) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 19.45
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (19.45) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 5 (23.81%) | 5.53% |
| Reviews | 2 (9.52%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 14 (66.67%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||